)
Ginkgo Bioworks (DNA) investor relations material
Ginkgo Bioworks Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Strategic focus shifted to autonomous labs as the core platform, with divestiture of the biosecurity business to enable targeted investment and operational focus on robotics and AI-driven lab automation.
Major contract wins include a $47 million deal with Pacific Northwest National Laboratory and a high-profile collaboration with OpenAI deploying GPT-5, demonstrating leadership in AI-integrated lab automation and achieving a 40% reduction in protein production costs.
Significant restructuring and cost controls over the past two years reduced annual cash burn by 55%, positioning the company for sustainable investment in core growth areas.
Expansion of the Boston autonomous lab from 50 to 100 racks is underway, aiming to showcase scalability and attract further commercial and research partnerships.
Partnerships announced with ARPA-H, University of Illinois Urbana-Champaign, Carnegie Mellon, Agricen, and Deep Origin, and launch of Datapoints business serving top pharma customers.
Financial highlights
Full year 2025 revenue was $170 million, down 25% year-over-year; Q4 2025 revenue was $33 million, down 24% from Q4 2024.
Cell engineering revenue for FY2025 was $133 million, down 24% year-over-year; Biosecurity revenue was $37 million, down 30%.
Adjusted EBITDA improved to -$36 million in Q4 2025 from -$57 million in Q4 2024; full-year Adjusted EBITDA was -$167 million, up from -$293 million in 2024.
Full year 2025 GAAP net loss was $(313) million, improved from $(547) million in 2024.
Cash burn for 2025 was $171 million, a 55% reduction from $383 million in 2024; year-end cash and equivalents totaled $423 million.
Outlook and guidance
No revenue guidance for 2026; focus is on cash burn, expected to be $125 million–$150 million, reflecting continued cost discipline and investment in autonomous labs.
2026 priorities include completing the biosecurity business divestiture, expanding autonomous lab capacity, and commercializing lab automation offerings through direct sales and cloud lab services.
- Q2 2024 revenue dropped 30% as restructuring and $47.9M goodwill impairment hit results.DNA
Q2 20241 Feb 2026 - Shifting to a focused, platform-driven model with new tools and data services for biotech innovation.DNA
Morgan Stanley 22nd Annual Global Healthcare Conference21 Jan 2026 - Q3 revenue up 61% to $89M, loss narrows, and 2024 guidance raised to $215–235M.DNA
Q3 202414 Jan 2026 - Direct sales, biopharma partnerships, and automation drive growth and market leadership.DNA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Cost cuts, new tools, and automation drive efficiency, but 2025 outlook remains cautious.DNA
Q4 202427 Dec 2025 - Flexible $500M shelf registration targets synthetic biology, automation, and biosecurity growth.DNA
Registration Filing16 Dec 2025 - Key votes on reverse stock split, officer exculpation, and charter updates to support NYSE compliance.DNA
Proxy Filing1 Dec 2025 - Votes sought on reverse split, officer exculpation, and charter updates to maintain NYSE listing.DNA
Proxy Filing1 Dec 2025 - 2025 proxy covers director elections, auditor ratification, say-on-pay, and governance updates.DNA
Proxy Filing1 Dec 2025
Next Ginkgo Bioworks earnings date
Next Ginkgo Bioworks earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)